Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects

Inclusion Criteria: * Sign the informed consent form before the trial, and fully understand the trial content, process, and possible adverse reactions. * Able to complete the study according to the requirements of the study protocol. * Subjects voluntarily agree to use effective non-pharmacological contraception methods from the signing of informed consent (14 days prior to signing for female subjects) until 3 months after the last dose, with no plans for pregnancy, sperm donation, or egg donation. * Male and female subjects aged 18 years and above. * Male subjects weighing ≥ 50.0 kg and female subjects weighing ≥ 45.0 kg; Body Mass Index (BMI) within the range of 19.0 to 27.0 kg/m\^2 (inclusive). Exclusion Criteria: * History of specific allergies (e.g., urticaria, exfoliative dermatitis, angioedema, or bronchial hyperresponsiveness), or allergic constitution (e.g., allergic to two or more drugs, foods such as milk and pollen), or known allergy to the components or analogs of this drug. * Serious history of cardiovascular, hepatic, renal, gastrointestinal, neurological, endocrine, respiratory, or psychiatric abnormalities, which the investigator considers inappropriate for participation. * Clinically significant abnormal findings as judged by the investigator, including physical examination, vital signs, electrocardiogram, or clinical laboratory tests. * History of or current pancreatitis. * History of hypoglycemia. * Estimated glomerular filtration rate (eGFR) \< 90 mL/m…